Prevalence and Predicting Risk Factors of Polypharmacy in Azar Cohort Population

• Published in: Iranian journal of pharmaceutical research : IJPR Vol. 21; no. 1
• Main Authors: Gharekhani, Afshin, Somi, Mohammadhossein, Ostadrahimi, Alireza, Hatefi, Ayda, Haji Kamanaj, Arash, Hassannezhad, Sina, Faramarzi, Elnaz
• Format: Journal Article
• Language: English
• Published: Brieflands 01.12.2022
• ISSN: 1735-0328; 1726-6890
• DOI: 10.5812/ijpr-126922

Background: As polypharmacy has some medically negative impacts, it has become a challenging issue for public health and affected people. Therefore, we decided to investigate the prevalence of polypharmacy and its predicting risk factors in the Azar cohort population. Methods: In this cross-sectional population-based cohort study, the prevalence of polypharmacy was evaluated in 15,001 subjects who participated in the Azar cohort study. We measured demographic characteristics (age, gender, socioeconomic status, smoking status, marital status, and education level), physical activity level, body mass index (BMI), blood pressure, multimorbidity (coexistence of two or more chronic diseases (CDs)), and polypharmacy status (a daily intake of five or more medicines for a minimum of 90 days). Results: Based on our results, 9.51% of the population had polypharmacy. The five most prescribed medications were drugs acting on the cardiovascular system (19.9%), central nervous system (16.7%), endocrine system (13.3%), NSAIDs (11.5%), and drugs used for musculoskeletal and joint diseases (11.4%). Being female, illiterate, and having the lowest tertile of physical activity level significantly increased the risk of polypharmacy. The risk of polypharmacy was 49.36 times higher in patients with four or more CDs than in those without. Conclusions: Our study emphasized the importance of routine monitoring to evaluate polypharmacy among those aged 35 to 59 and the elderly. Physicians should carefully assess drug suitability, especially in multimorbid and obese patients, to prevent excessive polypharmacy and its potentially negative impacts.